

## INVESTOR CONFERENCE CALL

---

Acrux (ASX: ACR) today confirms that it will host an Investor Conference Call to discuss the results for the year ended 30 June 2015 and provide an update on strategy.

Investor Conference Call details:

**Date: Thursday 13 August 2015**

**Time: 2pm (Australian Eastern Standard Time)**

A Q&A session will be held following the Company presentation. Shareholders and analysts are encouraged to participate by forwarding questions to [investor@acrux.com.au](mailto:investor@acrux.com.au) in advance of the Conference Call.

Acrux recommends participants dial in at least 5 to 10 prior to commencement of the call. A recording of the call will be made available in the 'Investor Centre' section of the Company website at: <http://www.acrux.com.au/>

Conference ID: 9745 872

### **Dial-in Details:**

Toll Free Dial-in Details: 1800 123 296

Australia: +61 2 8038 5221

New Zealand 0800 452 782

Singapore 800 616 2288

United States 1855 293 1544

United Kingdom 0808 234 0757

Canada 1855 5616 766

Hong Kong 800 908 865

## Contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

## About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including AXIRON<sup>®</sup>, Evamist<sup>®</sup> and Recuvyra<sup>™</sup>, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)

